Oragenics, Inc. OGEN · Stock Open Oragenics, Inc. in new tab
Oragenics, Inc. Analysis (OGEN)
Is Oragenics, Inc. a good investment? Oragenics, Inc. (OGEN) is currently trading at 0.5199 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.49. This relatively low multiple may signal that Oragenics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Oragenics, Inc. is expected to release its next earnings report on Nov. 16, 2026. The market consensus estimate for Forward EPS is -10.80.
Investor FAQ
Does Oragenics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Oragenics, Inc.?
Oragenics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 16, 2026. The company currently has a trailing EPS of 0.98.
Company Profile
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 28, 2010 | 1:20 |
| Jan. 22, 2018 | 1:10 |
| Jan. 23, 2023 | 1:50 |
| June 3, 2025 | 0.03 |
Community Discussion